Vor Biopharma (VOR) Common Equity (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Common Equity of -$150.4 million for Q1 2026, down 327.68% year-over-year from $66.1 million in Q1 2025, and up 8.45% quarter-over-quarter from -$164.3 million in Q4 2025.
Vor Biopharma (VOR) Common Equity (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Common Equity for 7 consecutive years, with -$150.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 327.68% year-over-year to -$150.4 million; the TTM figure through Mar 2026 stood at -$150.4 million (down 327.68% YoY), while the FY2025 annual figure was -$164.3 million, down 69.98% from the prior year.
- Common Equity improved to -$150.4 million in Q1 2026 per VOR's latest filing, from -$164.3 million in the prior quarter.
- Across five years, Common Equity topped out at $250.6 million in Q4 2022 and bottomed at -$2.2 billion in Q3 2025.
- Historically, Common Equity has averaged -$132.0 million across 5 years, with a median of $123.0 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity grew 18.39% — and 2025, when it tumbled 3150.49%.
- Vor Biopharma's Common Equity stood at $250.6 million in 2022, then plunged by 39.86% to $150.7 million in 2023, then plunged by 164.13% to -$96.7 million in 2024, then sank by 69.98% to -$164.3 million in 2025, then grew by 8.45% to -$150.4 million in 2026.
- Business Quant data shows VOR's Common Equity at -$150.4 million in Q1 2026, -$164.3 million in Q4 2025, and -$2.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -200.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.20 Mn |
| Mar 31, 2026 | -150.42 Mn |
| Dec 31, 2025 | -164.31 Mn |
| Sep 30, 2025 | -2.23 Bn |
| Jun 30, 2025 | -1.51 Bn |
| Mar 31, 2025 | 66.07 Mn |
| Dec 31, 2024 | -96.66 Mn |
| Sep 30, 2024 | 72.96 Mn |
| Jun 30, 2024 | 98.08 Mn |
| Mar 31, 2024 | 123.04 Mn |
| Dec 31, 2023 | 150.72 Mn |
| Sep 30, 2023 | 174.78 Mn |
| Jun 30, 2023 | 204.45 Mn |
| Mar 31, 2023 | 230.22 Mn |
| Dec 31, 2022 | 250.61 Mn |
| Sep 30, 2022 | 158.73 Mn |
| Jun 30, 2022 | 174.97 Mn |
| Mar 31, 2022 | 194.45 Mn |
| Dec 31, 2021 | 216.26 Mn |
| Sep 30, 2021 | 232.96 Mn |